INBRX-106

INBRX-106 (ordastobart) is Inhibrx Biosciences' hexavalent OX40 agonist antibody, now the most credible asset in a drug class that has produced nothing but failures for a decade. The randomized Phase 2 HexAgon-HN interim on May 11, 2026 reported a 44% confirmed objective response rate for the INBRX-106 plus pembrolizumab combination versus 21.4% for pembrolizumab alone in first-line PD-L1 high head and neck cancer; patient numbers at interim were not disclosed, so the confidence interval on that delta is not public. If the signal holds through maturation, this is the first OX40 agonist with a real shot at approval.

INBRX-106 is a novel compound, never approved anywhere, and the lead program is the Phase 2 randomized portion of NCT06295731 (HexAgon-HN) in first-line locally advanced or metastatic head and neck squamous cell carcinoma restricted to PD-L1 combined positive score (CPS) ≥20 [1]. PD-L1 CPS is a pathology scoring method that counts PD-L1 positive tumor cells, lymphocytes, and macrophages divided by total viable tumor cells, times 100; CPS≥20 identifies roughly the top third of HNSCC patients and is the subset with the strongest single-agent checkpoint responses. Enrollment target is 410 and the trial is listed as active, not recruiting. A supporting Phase 1 first-in-human study (NCT04198766) with a 340-patient enrollment target across multiple solid tumor cohorts is ongoing in parallel and includes a pembrolizumab combination arm [2]; a small investigator-sponsored neoadjuvant TNBC trial (NCT06353997) is enrolling at Providence Cancer Institute [3]. No breakthrough therapy, fast track, or orphan drug designations have been publicly disclosed. The company reported the HexAgon-HN interim objective response rate benefit on May 11, 2026 [4]. Mature Phase 2 data with duration of response and progression-free survival are the next catalyst; the HexAgon-HN protocol lists overall survival as a secondary endpoint but the registrational path has not been publicly defined. Timing for the mature readout has not been publicly committed; an educated guess based on enrollment completion and the need for 6 to 12 months of follow-up is 2H 2026 to 1H 2027. Inhibrx Biosciences (NASDAQ: INBX) is the 2024 spinoff that retained the INBRX-106 and INBRX-109 oncology assets when Sanofi acquired the parent Inhibrx for its INBRX-101 alpha-1 antitrypsin program; three 8-K filings in 2025 and 2026 indicate active catalyst communication to the market [5].

OX40 (gene name TNFRSF4) is a costimulatory receptor on the surface of T cells that acts as an accelerator pedal for the immune response. When a T cell encounters a tumor antigen and starts to activate, OX40 appears on its surface; binding of its natural ligand OX40L on dendritic cells tells the T cell to proliferate, survive longer, and resist shutdown signals from regulatory T cells. There is a second clinically relevant mechanism: OX40 is highly expressed on intratumoral regulatory T cells (Tregs), and OX40 agonism can deplete or destabilize this immunosuppressive population inside the tumor microenvironment, lifting a local brake on effector T cells. The therapeutic logic combines both: push the accelerator on effector T cells and remove the Treg brake, especially alongside PD-1 blockade. The mechanism is well-supported in mouse models. The problem has been clinical translation. Prior OX40 agonists, including MOXR0916 (pogalizumab, Roche/Genentech), GSK3174998 (GSK), tavolimab (MEDI0562, MedImmune), BMS-986178 (BMS), ivuxolimab (PF-04518600, Pfizer), and INCAGN01949 (Incyte/Agenus), all generated weak or no single-agent antitumor activity and most have been discontinued. The current scientific consensus is that OX40 signaling requires tight receptor clustering on the T cell surface, and conventional bivalent IgG antibodies simply don't cluster the receptor hard enough to trigger the downstream signal; bivalent agonists have typically depended on Fc-gamma receptor (FcγR) engagement on neighboring cells to achieve any crosslinking at all, which is inconsistent in the tumor microenvironment. INBRX-106 is hexavalent, meaning six OX40 binding sites per molecule, and was engineered specifically to drive the receptor crosslinking intrinsically rather than depending on FcγR help. Holay et al. (J Immunother Cancer, 2025) showed that INBRX-106 drives dose-dependent T cell activation and superior preclinical antitumor responses versus bivalent benchmarks, with receptor clustering density as the proposed mechanism [6]. This is the strongest mechanistic rationale any OX40 agonist has brought to the clinic.

NCT06295731 (HexAgon-HN) is a randomized Phase 2 in first-line locally advanced or metastatic head and neck squamous cell carcinoma, restricted to PD-L1 CPS ≥20, with INBRX-106 plus pembrolizumab versus pembrolizumab monotherapy as the comparator [1]. Primary endpoint is objective response rate by independent central review; enrollment target is 410 and the study is now active, not recruiting. The PD-L1 CPS≥20 restriction is a reasonable enrichment choice because this population responds best to checkpoint monotherapy and provides a cleaner background against which to measure a combination contribution. Picking pembrolizumab monotherapy as the comparator is appropriate: KEYNOTE-048 established single-agent pembro as a 1L option in CPS≥20 HNSCC, and the delta is interpretable without needing a chemo arm. The May 2026 interim reported 44% confirmed ORR for the combination versus 21.4% for pembrolizumab alone [4]. The 21.4% control rate is consistent with KEYNOTE-048 ORR in the CPS≥20 subset, which argues the comparator arm is behaving as expected rather than underperforming by chance. The number of patients analyzed at interim and the confidence interval on the ORR difference were not disclosed in the May 11 release; a doubling of ORR is encouraging regardless, but the statistical weight behind that doubling cannot be assessed from public data. Mature readouts will need to include duration of response and progression-free survival; a short-lived ORR advantage would gut the registrational case for a checkpoint combination. Companion neoadjuvant Phase 2 work in TNBC (NCT06353997) is a separate hypothesis-generating effort at a single academic site [3].

Our model estimates a 4% chance this drug is eventually approved. It starts from the historical base rate for Phase 2 drugs in this area (about 13%), then adjusts using ten facts about the trial and sponsor. What moves the number most: it is helped by larger-than-typical enrollment for this phase and more secondary endpoints than usual; it is held back by the sponsor's thin or weak approval record and weak or limited earlier-phase results. The other facts land near average for this stage, so they leave the estimate roughly where the base rate put it.

Efficacy risk: the 44% versus 21.4% ORR gap at interim is encouraging but not conclusive. ORR in head and neck cancer does not reliably predict overall survival, and the FDA has become sharper about requiring OS or PFS evidence before approving checkpoint combinations. The response rate advantage could compress at maturation if the combination accelerates responses without extending them. OX40 agonists have specifically struggled to translate preclinical T cell activation into durable clinical benefit. Safety risk: forcing stronger T cell activation on top of PD-1 blockade raises the ceiling for immune-related adverse events. OX40 agonism can drive cytokine release, hepatitis, pneumonitis, and colitis beyond the pembrolizumab baseline. The 340-patient Phase 1 program [2] has advanced INBRX-106 into randomized Phase 2 testing, which implies the tolerability profile was acceptable enough to clear the standard safety gate, but specific Grade 3+ immune-related adverse event rates and dose-limiting toxicities from that study have not been consolidated into the public record beyond conference abstracts; a Phase 3 safety database at scale often surfaces issues that small Phase 2 cohorts miss. Execution risk: Inhibrx Biosciences is a small-cap biotech with concentrated pipeline risk, and HexAgon-HN is the lead asset. A Phase 3 program will require either significant financing or a partnership. Commercial risk: the 1L PD-L1 CPS≥20 HNSCC addressable population in the US is under 10,000 patients per year. At roughly $200K per patient-year for a checkpoint combination, that is a $1 to 2 billion peak US revenue envelope on full penetration, meaningful but not a blockbuster without expansion into broader PD-L1 populations or other tumor types. Competitive pressure from ES102, a hexavalent OX40 agonist from Elpiscience Biopharma now in Phase 2 combination with toripalimab in NSCLC [7], means the hexavalent design is no longer uniquely INBRX-106's story.

Worth watching, high priority. This is the first OX40 agonist in a decade of class failures to produce a credible randomized Phase 2 signal, and the hexavalent clustering story has a peer-reviewed mechanistic underpinning that explains why prior bivalent agonists did not work [6]. If mature HexAgon-HN data confirm the ORR delta with durable responses and a PFS signal, INBRX-106 moves from speculative to the leading OX40 asset in development and will almost certainly draw partnership interest for pivotal expansion into other PD-L1 driven tumors. Specific signals to watch: the disclosed n for the next data cut (critical for assessing statistical reliability of the ORR delta), median duration of response at the mature Phase 2 readout, PFS hazard ratio in the HexAgon-HN population, Grade 3 or higher immune-related adverse event rates in the combination arm versus pembro alone, and whether Inhibrx Biosciences discloses a Phase 3 design and a partner. Expected timing is 2H 2026 or 1H 2027 based on the active-not-recruiting status; the three 2025 and 2026 8-K filings point to active catalyst management [5]. Inhibrx Biosciences spun out of the original Inhibrx in May 2024 when Sanofi acquired the alpha-1 antitrypsin program, leaving INBX with a focused oncology pipeline of INBRX-106 and the DR5 agonist INBRX-109. The company's market cap is small relative to the asset's potential, which cuts both ways: significant upside on positive Phase 3 data and significant dilution risk financing the trial. Check back after the next HexAgon-HN data cut.